Key result
The cGAS-STING pathway links to cardiac dysfunction and emerges as a potential target for cardiomyopathy.
Why the study?
There is growing interest in the precise relationship between cGAS-STING pathway activation and the initiation or progression of cardiovascular diseases to identify novel therapeutic targets for cardiomyopathy.
Targeting the cGAS-STING pathway may offer novel therapeutic strategies for cardiomyopathy by modulating innate immune and inflammatory responses in the myocardium.
May support cGAS-STING targeting in cardiomyopathy; hypothesis-generating and requires randomized trials before clinical consideration.
As an innate immune route of defense against microbial infringement, cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS)- stimulator of interferon genes (STING) signaling does not simply participate in amplifying inflammatory responses via releasing type-I interferon (IFN) or enhance the expression of pro-inflammatory genes, but also interplays with multifarious pathophysiological activities, such as autophagy, apoptosis, pyroptosis, ferroptosis, and senescence in a broad repertoire of cells like endothelial cells, macrophages and cardiomyocyte. Thus, the cGAS-STING pathway is closely linked with aberrant heart morphologically and functionally via these mechanisms. The past few decades have witnessed an increased interest in the exact relationship between the activation of the cGAS-STING pathway and the initiation or development of certain cardiovascular diseases (CVD). A group of scholars has gradually investigated the perturbation of myocardium affected by the overactivation or suppression of the cGAS-STING. This review focuses on how the cGAS-STING pathway interweaves with other pathways and creates a pattern of dysfunction associated with cardiac muscle. This sets treatments targeting the cGAS-STING pathway apart from traditional therapeutics for cardiomyopathy and achieves better clinical value.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2023) conducted a review in Cardiovascular diseases and cardiomyopathy. cGAS-STING pathway targeting was evaluated. The cGAS-STING pathway interweaves with other pathways to create a pattern of dysfunction associated with cardiac muscle, making it a potential therapeutic target for cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: